
New chief executive for Cipla
pharmafile | November 30, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Cipla, Subhanu Saxena
Indian pharma firm Cipla has announced the appointment of Novartis’ Subhanu Saxena as its chief executive.
Saxena joins Cipla in February with 25+ years’ work experience, having worked with companies such as Citicorp, The Boston Consulting Group, and PepsiCo, across markets in Europe, North America, Africa and Asia.
In his last assignment he led the global product strategy and commercialisation functions at Novartis Pharma AG. In this role, Saxena was a part of the global pharma executive committee with responsibility for marketing, sales, global medical affairs and health economics.
Cipla chairman Dr Yusuf Hamied said: “We are delighted to have found such a good match for Cipla in Subhanu. Cipla has a strong vision for the future. I am confident Subhanu will build on Cipla’s core values to deliver the next phase of growth, competitiveness and return on shareholder value.”
Related Content

Diagnosing the drug supply: Exposing the bad practice of manufacturers in the developing world
The world needs cheap generic drugs and Indian manufacturers offer a steady supply. However the …

Cipla halts HIV drug production due to delayed government funding
Indian pharmaceutical company Cipla has halted production of its child-friendly antiretroviral HIV treatment Lopinavir (ABT-378) …

India’s NPPA identifies 634 non-compliant drug pricings
India’s National Pharmaceutical Pricing Authority (NPPA) has revealed that as many as 634 drugs from …






